InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: I_luv_cydy post# 36587

Saturday, 02/16/2019 8:06:52 PM

Saturday, February 16, 2019 8:06:52 PM

Post# of 232883
I will tell the entire board right now that CYDY may seem weak right now because it still trades on the OTC and still looking for approval. But I believe that Pro-140 has a good shot at potentially becoming another Humira. Humira generates $15 billion per year for AbbVie. The reason why is that HIV is just the start, then you have potential with cancer metastasis, then GvHD, then multiple sclerosis, NASH, and other autoimmune disorders. I believe that the future of this product is strong. yes it's going to take years to get there I get that, but I believe it has the potential to become like Humira. That's what I'm holing out for. Humira also just started off as a monoclonal antibody only for 1 indication. Humira's first approval was back in 2002 for only Rheumatoid arthritis, from there it expanded to other indications. I believe Pro-140 has the ability to do the same. It would be smart for a big pharma to get its hands on this monoclonal antibody now, because it's very rare for 1 drug product like Pro-140 to be able to target multiple indications.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News